Background Protein ubiquitination and/or degradation by the ubiquitin/proteasome system (UPS) have been recognized as critical mechanisms in the regulation of numerous essential cellular functions. The importance of the UPS in viral pathogenesis has become increasingly apparent. Using murine cardiomyocytes, we have previously demonstrated that the UPS plays a key role in the replication of coxsackievirus B3 (CVB3), an important human pathogen associated with various diseases. To further elucidate the underlying mechanisms, we examined the interplay between the UPS and CVB3, focusing on the role of ubiquitination in viral lifecycle. Methodology/Principal Findings As assessed by in situ hybridization, Western blot, and plaque assay, we showed that proteasome inhibition decreased CVB3 RNA replication, protein synthesis, and viral titers in HeLa cells. There were no apparent changes in 20S proteasome activities following CVB3 infection. However, we found viral infection led to an accumulation of protein-ubiquitin conjugates, accompanied by a decreased protein expression of free ubiquitin, implicating an important role of ubiquitination in the UPS-mediated viral replication. Using small-interfering RNA, we demonstrated that gene-silencing of ubiquitin significantly reduced viral titers, possibly through downregulation of protein ubiquitination and subsequent alteration of protein function and/or degradation. Inhibition of deubiquitinating enzymes apparently enhances the inhibitory effects of proteasome inhibitors on CVB3 replication. Finally, by immunoprecipitation, we showed that coxsackieviral polymerase 3D was post-translationally modified by ubiquitination and such modification might be a prerequisite for its function in transcriptional regulation of viral genome. Conclusion Coxsackievirus infection promotes protein ubiquitination, contributing to effective viral replication, probably through ubiquitin modification of viral polymerase.
References
[1]
Opavsky MA, Martino T, Rabinovitch M, Penninger J, Richardson C, et al. (2002) Enhanced ERK-1/2 activation in mice susceptible to coxsackievirus-induced myocarditis. J Clin Invest 109: 1561–1569.
[2]
Luo H, Yanagawa B, Zhang J, Luo Z, Zhang M, et al. (2002) Coxsackievirus B3 replication is reduced by inhibition of the extracellular signal-regulated kinase (ERK) signaling pathway. J Virol 76: 3365–3373.
[3]
Cunningham KA, Chapman NM, Carson SD (2003) Caspase-3 activation and ERK phosphorylation during CVB3 infection of cells: influence of the coxsackievirus and adenovirus receptor and engineered variants. Virus Res 92: 179–186.
[4]
Liu P, Aitken K, Kong YY, Opavsky MA, Martino T, et al. (2000) The tyrosine kinase p56lck is essential in coxsackievirus B3-mediated heart disease. Nat Med 6: 429–434.
[5]
Fuse K, Chan G, Liu Y, Gudgeon P, Husain M, et al. (2005) Myeloid differentiation factor-88 plays a crucial role in the pathogenesis of Coxsackievirus B3-induced myocarditis and influences type I interferon production. Circulation 112: 2276–2285.
[6]
Esfandiarei M, Luo H, Yanagawa B, Suarez A, Dabiri D, et al. (2004) Protein kinase B/Akt regulates coxsackievirus B3 replication through a mechanism which is not caspase dependent. J Virol 78: 4289–4298.
[7]
Yuan J, Zhang J, Wong BW, Si X, Wong J, et al. (2005) Inhibition of glycogen synthase kinase 3beta suppresses coxsackievirus-induced cytopathic effect and apoptosis via stabilization of beta-catenin. Cell Death Differ 12: 1097–1106.
[8]
Si X, McManus BM, Zhang J, Yuan J, Cheung C, et al. (2005) Pyrrolidine dithiocarbamate reduces coxsackievirus B3 replication through inhibition of the ubiquitin-proteasome pathway. J Virol 79: 8014–8023.
[9]
Luo H, Zhang J, Dastvan F, Yanagawa B, Reidy MA, et al. (2003) Ubiquitin-dependent proteolysis of cyclin D1 is associated with coxsackievirus-induced cell growth arrest. J Virol 77: 1–9.
[10]
Wolf DH, Hilt W (2004) The proteasome: a proteolytic nanomachine of cell regulation and waste disposal. Biochim Biophys Acta 1695: 19–31.
[11]
Schwartz AL, Ciechanover A (1999) The ubiquitin-proteasome pathway and pathogenesis of human diseases. Annu Rev Med 50: 57–74.
[12]
Amerik AY, Hochstrasser M (2004) Mechanism and function of deubiquitinating enzymes. Biochim Biophys Acta 1695: 189–207.
[13]
Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, et al. (2005) A genomic and functional inventory of deubiquitinating enzymes. Cell 123: 773–786.
[14]
Glotzer M, Murray AW, Kirschner MW (1991) Cyclin is degraded by the ubiquitin pathway. Nature 349: 132–138.
[15]
Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, et al. (1995) Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682–685.
[16]
Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129–1136.
[17]
Palombella VJ, Rando OJ, Goldberg AL, Maniatis T (1994) The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78: 773–785.
[18]
Roos-Mattjus P, Sistonen L (2004) The ubiquitin-proteasome pathway. Ann Med 36: 285–295.
[19]
Hicke L (2001) Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2: 195–201.
[20]
Bres V, Kiernan RE, Linares LK, Chable-Bessia C, Plechakova O, et al. (2003) A non-proteolytic role for ubiquitin in Tat-mediated transactivation of the HIV-1 promoter. Nat Cell Biol 5: 754–761.
[21]
Ott DE, Coren LV, Chertova EN, Gagliardi TD, Schubert U (2000) Ubiquitination of HIV-1 and MuLV Gag. Virology 278: 111–121.
[22]
Patnaik A, Chau V, Wills JW (2000) Ubiquitin is part of the retrovirus budding machinery. Proc Natl Acad Sci U S A 97: 13069–13074.
[23]
Peloponese JM Jr, Iha H, Yedavalli VR, Miyazato A, Li Y, et al. (2004) Ubiquitination of human T-cell leukemia virus type 1 tax modulates its activity. J Virol 78: 11686–11695.
[24]
Schubert U, Ott DE, Chertova EN, Welker R, Tessmer U, et al. (2000) Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc Natl Acad Sci U S A 97: 13057–13062.
[25]
Strack B, Calistri A, Accola MA, Palu G, Gottlinger HG (2000) A role for ubiquitin ligase recruitment in retrovirus release. Proc Natl Acad Sci U S A 97: 13063–13068.
[26]
Luo H, Zhang J, Cheung C, Suarez A, McManus BM, et al. (2003) Proteasome inhibition reduces coxsackievirus B3 replication in murine cardiomyocytes. Am J Pathol 163: 381–385.
[27]
Mimnaugh EG, Chen HY, Davie JR, Celis JE, Neckers L (1997) Rapid deubiquitination of nucleosomal histones in human tumor cells caused by proteasome inhibitors and stress response inducers: effects on replication, transcription, translation, and the cellular stress response. Biochemistry 36: 14418–14429.
[28]
Jentsch S, Seufert W, Hauser HP (1991) Genetic analysis of the ubiquitin system. Biochim Biophys Acta 1089: 127–139.
[29]
Kirschner LS, Stratakis CA (2000) Structure of the human ubiquitin fusion gene Uba80 (RPS27a) and one of its pseudogenes. Biochem Biophys Res Commun 270: 1106–1110.
[30]
Wilkinson KD (1997) Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. Faseb J 11: 1245–1256.
[31]
de Groot RJ, Rumenapf T, Kuhn RJ, Strauss EG, Strauss JH (1991) Sindbis virus RNA polymerase is degraded by the N-end rule pathway. Proc Natl Acad Sci U S A 88: 8967–8971.
[32]
Morita E, Sundquist WI (2004) Retrovirus budding. Annu Rev Cell Dev Biol 20: 395–425.
[33]
Shackelford J, Pagano JS (2004) Tumor viruses and cell signaling pathways: deubiquitination versus ubiquitination. Mol Cell Biol 24: 5089–5093.
[34]
Furman MH, Ploegh HL (2002) Lessons from viral manipulation of protein disposal pathways. J Clin Invest 110: 875–879.
[35]
Fan Z, Zhuo Y, Tan X, Zhou Z, Yuan J, et al. (2006) SARS-CoV nucleocapsid protein binds to hUbc9, a ubiquitin conjugating enzyme of the sumoylation system. J Med Virol 78: 1365–1373.
[36]
Yu X, Yu Y, Liu B, Luo K, Kong W, et al. (2003) Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302: 1056–1060.
[37]
Losick VP, Schlax PE, Emmons RA, Lawson TG (2003) Signals in hepatitis A virus P3 region proteins recognized by the ubiquitin-mediated proteolytic system. Virology 309: 306–319.
[38]
Lawson TG, Gronros DL, Evans PE, Bastien MC, Michalewich KM, et al. (1999) Identification and characterization of a protein destruction signal in the encephalomyocarditis virus 3C protease. J Biol Chem 274: 9871–9880.
[39]
Lawson TG, Sweep ME, Schlax PE, Bohnsack RN, Haas AL (2001) Kinetic analysis of the conjugation of ubiquitin to picornavirus 3C proteases catalyzed by the mammalian ubiquitin-protein ligase E3alpha. J Biol Chem 276: 39629–39637.
[40]
Love KR, Catic A, Schlieker C, Ploegh HL (2007) Mechanisms, biology and inhibitors of deubiquitinating enzymes. Nat Chem Biol 3: 697–705.
[41]
Gong B, Cao Z, Zheng P, Vitolo OV, Liu S, et al. (2006) Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 126: 775–788.
